New pharmaceutical company opens in Canada
Sterinova to specialise in developing and manufacturing sterile ready-to-use injectable products.
Industry expert Kunal Jaiswal to head strategic development for Catalent's clinical supply services business
Will lead the company’s ongoing efforts to anticipate and act upon industry trends and technologies that may affect study sponsors, clinical sites, and patients, and to inform the development and delivery of current and future clinical supply services.
SOTIO and NBE Therapeutics sign collaboration and license agreement for next-generation ADCs
Collaboration will focus on the discovery, non-clinical development and manufacturing of novel ADC products against undisclosed targets.
A silicone antifoam agent SILFAR® S 184
Get to know SILFAR® S 184 - a silicone antifoam agent developed specifically for the pharmaceutical sector. Typical applications for SILFAR® S 184 include antiflatulent, antacid and fermented preparations.
Hikma Ventures invests in Propeller Health for the enhancement of leading respiratory technology platform
Propeller Health has developed a digital platform that integrates information from multiple sources and uses machine intelligence to recommend an optimal path therapy for individuals who suffer from COPD, asthma and other respiratory diseases.
Positive results from two pivotal Phase 3 studies of Revefenacin for the treatment of COPD
Top-line results across more than 1,250 moderate to very severe COPD patients confirmed that both Phase III studies met their primary efficacy endpoint.
Colombian pharmaceutical market to see strong market growth, surpassing $7 billion by 2020
Substantial rise can be attributed to increased drug consumption, caused by a rising disease burden, and government initiatives in the public healthcare sector.
FDA awards 21 grants to stimulate product development for rare diseases
The new clinical trial research grants total more then $23 million over the next 4 years.
FDA approves Genentech’s cancer immunotherapy Tecentriq for people with a specific type of metastatic lung cancer
First and only anti-PDL1 cancer immunotherapy approved by the FDA for metastatic non-small cell lung cancer.